Trajectories of posttraumatic stress symptoms during and after Narrative Exposure Therapy (NET) in refugees.


Journal

BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559

Informations de publication

Date de publication:
17 06 2020
Historique:
received: 21 06 2019
accepted: 09 06 2020
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 3 11 2020
Statut: epublish

Résumé

Trauma-focused therapy approaches are recommended as treatment for posttraumatic stress disorder (PTSD). This includes the treatment of trauma-related suffering in refugee populations. However, there is a lack of knowledge about symptom trajectories in refugees living in volatile conditions. This has led to fear of "retraumatisation" and general skepticism in clinicians concerning the use of exposure therapy. To test the relevance of this concern, we investigated PTSD symptom trajectories and potentially influencing factors during the course of Narrative Exposure Therapy (NET) in a refugee sample living in Germany. Refugees filled out the PTSD Checklist prior to each treatment session and also during follow-up interviews. Therapists continuously documented positive and negative life events as well as the content of the treatment sessions. Additionally, structured clinical interviews were conducted pre-treatment and at follow-up time points. On average, clients presented with substantial decreases in PTSD symptoms already during and after NET. However, symptom trajectories differed and ranged from fast responders to slow responders to no immediate response during treatment. Importantly, a persistent worsening of symptoms was not observed, also not after exposure to the most distressing events. In contrast, stressful life experiences seemed to aggravate PTSD symptoms. Consistent with earlier studies, NET leads to clinically and behaviorally relevant reductions in PTSD symptoms both throughout and following treatment in refugees living in volatile conditions. Concerns about imaginal exposure in refugees were not substantiated. While stressful life events contributed to transient symptom increases, they weren't found to prevent the overall effectiveness of NET. NCT02852616.

Sections du résumé

BACKGROUND
Trauma-focused therapy approaches are recommended as treatment for posttraumatic stress disorder (PTSD). This includes the treatment of trauma-related suffering in refugee populations. However, there is a lack of knowledge about symptom trajectories in refugees living in volatile conditions. This has led to fear of "retraumatisation" and general skepticism in clinicians concerning the use of exposure therapy.
METHODS
To test the relevance of this concern, we investigated PTSD symptom trajectories and potentially influencing factors during the course of Narrative Exposure Therapy (NET) in a refugee sample living in Germany. Refugees filled out the PTSD Checklist prior to each treatment session and also during follow-up interviews. Therapists continuously documented positive and negative life events as well as the content of the treatment sessions. Additionally, structured clinical interviews were conducted pre-treatment and at follow-up time points.
RESULTS
On average, clients presented with substantial decreases in PTSD symptoms already during and after NET. However, symptom trajectories differed and ranged from fast responders to slow responders to no immediate response during treatment. Importantly, a persistent worsening of symptoms was not observed, also not after exposure to the most distressing events. In contrast, stressful life experiences seemed to aggravate PTSD symptoms.
CONCLUSIONS
Consistent with earlier studies, NET leads to clinically and behaviorally relevant reductions in PTSD symptoms both throughout and following treatment in refugees living in volatile conditions. Concerns about imaginal exposure in refugees were not substantiated. While stressful life events contributed to transient symptom increases, they weren't found to prevent the overall effectiveness of NET.
TRIAL REGISTRATION
NCT02852616.

Identifiants

pubmed: 32552778
doi: 10.1186/s12888-020-02720-y
pii: 10.1186/s12888-020-02720-y
pmc: PMC7298826
doi:

Banques de données

ClinicalTrials.gov
['NCT02852616']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

312

Subventions

Organisme : H2020 European Research Council
ID : ERC-2012-AdG 323977 MemoTV
Pays : International
Organisme : vivo international e.V.
ID : -
Pays : International

Références

Clin Psychol Psychother. 2017 Jul;24(4):807-825
pubmed: 26676201
Cochrane Database Syst Rev. 2013 Dec 13;(12):CD003388
pubmed: 24338345
Int J Soc Psychiatry. 2015 Feb;61(1):17-26
pubmed: 24869847
J Nerv Ment Dis. 2018 Jan;206(1):61-68
pubmed: 29194088
Perm J. 2013 Winter;17(1):70-6
pubmed: 23596375
Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):345-59
pubmed: 20633738
J Psychiatr Res. 2014 Jul;54:1-10
pubmed: 24726027
Torture. 2017;27(1):13-27
pubmed: 28607227
Eur J Psychotraumatol. 2016 Nov 09;7:32106
pubmed: 27834172
Lancet. 2005 Nov 5;366(9497):1604-5; author reply 1605
pubmed: 16271637
J Consult Clin Psychol. 2002 Aug;70(4):880-6
pubmed: 12182271
J Nerv Ment Dis. 2001 Dec;189(12):838-45
pubmed: 11794577
Behav Res Ther. 2013 Oct;51(10):641-7
pubmed: 23916633
Eur J Psychotraumatol. 2017 Oct 10;8(sup2):1377552
pubmed: 29163866
J Consult Clin Psychol. 1991 Feb;59(1):12-9
pubmed: 2002127
PLoS One. 2017 Feb 2;12(2):e0171030
pubmed: 28151992
J Trauma Stress. 2006 Oct;19(5):597-610
pubmed: 17075914
J Trauma Stress. 2000 Apr;13(2):181-91
pubmed: 10838669
Behav Res Ther. 2010 Apr;48(4):312-20
pubmed: 20056195
Behav Res Ther. 2016 Feb;77:68-77
pubmed: 26731171
Clin Psychol Rev. 2007 Jul;27(6):715-23
pubmed: 17316941
Clin Psychol Rev. 2018 Jul;63:66-79
pubmed: 29936342
Eur J Psychotraumatol. 2017 Nov 07;8(sup2):1389205
pubmed: 29163869
Psychother Psychosom. 2011;80(6):345-52
pubmed: 21829046
Front Psychiatry. 2018 Aug 03;9:352
pubmed: 30123145
BMC Int Health Hum Rights. 2015 Oct 28;15:29
pubmed: 26510473
J Trauma Stress. 2015 Dec;28(6):489-98
pubmed: 26606250
J Clin Psychol. 2017 Sep;73(9):1048-1063
pubmed: 27880002
J Consult Clin Psychol. 2013 Jun;81(3):383-93
pubmed: 23276122
PLoS One. 2017 May 12;12(5):e0177617
pubmed: 28498865
J Trauma Stress. 2009 Aug;22(4):287-93
pubmed: 19637322
J Gen Intern Med. 2007 Nov;22(11):1596-602
pubmed: 17874169
JAMA. 2015 Nov 10;314(18):1966-7
pubmed: 26547468
Behav Res Ther. 2004 Mar;42(3):277-92
pubmed: 14975770
Psychoneuroendocrinology. 2014 Nov;49:280-9
pubmed: 25127086
Clin Psychol Rev. 2010 Dec;30(8):1030-9
pubmed: 20832922
Transl Psychiatry. 2014 Jun 24;4:e403
pubmed: 24959896
Depress Anxiety. 2016 Sep;33(9):807-15
pubmed: 27321062
Clin Psychol Psychother. 2018 Nov;25(6):827-841
pubmed: 30079583
Psychol Trauma. 2017 Aug;9(Suppl 1):137-144
pubmed: 27831734
BMC Psychiatry. 2017 Nov 28;17(1):379
pubmed: 29183285
J Trauma Stress. 2003 Dec;16(6):555-62
pubmed: 14690352
Psychol Assess. 2006 Sep;18(3):262-8
pubmed: 16953729
Psychol Bull. 1986 Jan;99(1):20-35
pubmed: 2871574
Behav Ther. 2012 Dec;43(4):790-800
pubmed: 23046781
Semin Cell Dev Biol. 2018 May;77:144-152
pubmed: 29174456
Psychol Assess. 2016 Nov;28(11):1392-1403
pubmed: 26751087
J Consult Clin Psychol. 2002 Aug;70(4):1022-8
pubmed: 12182265
Eur J Psychotraumatol. 2015 Aug 14;6:28186
pubmed: 26290178
BMC Psychiatry. 2014 Mar 27;14:90
pubmed: 24670251
J Ment Health. 2019 Dec;28(6):662-676
pubmed: 28485636
Nord J Psychiatry. 2015;69(7):483-96
pubmed: 25733025
Psychol Trauma. 2017 May;9(3):282-291
pubmed: 27710003
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
J Consult Clin Psychol. 2013 Jun;81(3):394-404
pubmed: 23339535
Cogn Behav Ther. 2010;39(2):81-91
pubmed: 19816834
Psychol Assess. 2016 Nov;28(11):1379-1391
pubmed: 26653052
J Trauma Stress. 2010 Aug;23(4):437-45
pubmed: 20684019
Psychophysiology. 2020 Jan;57(1):e13353
pubmed: 30807662
JAMA. 2005 Aug 3;294(5):602-12
pubmed: 16077055
Depress Anxiety. 2016 Sep;33(9):792-806
pubmed: 27126398
Psychother Psychosom Med Psychol. 2018 Jan;68(1):22-29
pubmed: 28470633

Auteurs

Elisa Kaltenbach (E)

Department of Psychology, University of Konstanz, Konstanz, Germany. elisa.kaltenbach@iwk.nshealth.ca.
Centre for Research in Family Health, IWK Health Centre, Halifax, NS, Canada. elisa.kaltenbach@iwk.nshealth.ca.
Vivo International e.V., Konstanz, Germany. elisa.kaltenbach@iwk.nshealth.ca.

Katharin Hermenau (K)

Department of Psychology, University of Konstanz, Konstanz, Germany.
Vivo International e.V., Konstanz, Germany.

Maggie Schauer (M)

Department of Psychology, University of Konstanz, Konstanz, Germany.
Vivo International e.V., Konstanz, Germany.

Katalin Dohrmann (K)

Department of Psychology, University of Konstanz, Konstanz, Germany.
Vivo International e.V., Konstanz, Germany.

Thomas Elbert (T)

Department of Psychology, University of Konstanz, Konstanz, Germany.
Vivo International e.V., Konstanz, Germany.

Inga Schalinski (I)

Department of Psychology, University of Konstanz, Konstanz, Germany.
Vivo International e.V., Konstanz, Germany.
Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Institute of Medical Psychology, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH